[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201071259A1 - Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина - Google Patents

Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина

Info

Publication number
EA201071259A1
EA201071259A1 EA201071259A EA201071259A EA201071259A1 EA 201071259 A1 EA201071259 A1 EA 201071259A1 EA 201071259 A EA201071259 A EA 201071259A EA 201071259 A EA201071259 A EA 201071259A EA 201071259 A1 EA201071259 A1 EA 201071259A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
hydrogen
halogen
independently represent
triftoromethilphenyl
Prior art date
Application number
EA201071259A
Other languages
English (en)
Other versions
EA017960B1 (ru
Inventor
Джузеппе Альваро
Эмилиано Кастильони
Агостино Мараско
Original Assignee
Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд. filed Critical Глэксо Уэлкам Мэньюфэкчуринг Пте Лтд.
Publication of EA201071259A1 publication Critical patent/EA201071259A1/ru
Publication of EA017960B1 publication Critical patent/EA017960B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Соединения формулы (I) или его фармацевтически приемлемая сольгде R представляет собой водород или Салкил; R1 представляет собой водород, Салкил, С(О)ОН, C(O)NHили (Салкилен)R10; R2 и R3 независимо представляют собой водород, Салкил или R2 вместе с R3 и вместе с атомом углерода, к которому они присоединены, образуют Сциклоалкильную группу; R4 представляет собой Салкил, Салкокси или галоген; R5 и R7 независимо представляют собой водород, гидрокси, галоген, C(O)NH, С(О)ОН или (Салкилен)R10; R6 и R8 независимо представляют собой водород или галоген; R9 представляет собой водород, (Салкилен)R10, C(O)NH, С(О)ОН или R9 вместе с R образуют 6-членное гетероциклическое кольцо, необязательно содержащее, кроме того, гетероатом, выбранный из кислорода, серы или азота; R10 представляет собой водород, галоген, гидрокси, C(O)NH, C(O)NH(Салкил), С(О)N(Салкил)или С(О)ОН; n равно 0, 1 или 2; способы их получения, содержащие их композиции и их применение при лечении заболеваний и состояний, при которых полезным является антагонизм NK1.
EA201071259A 2008-05-01 2009-04-29 Производные 1,8-диазоспиро[4,5]декан-8-карбоксамида, обладающие антагонистической активностью в отношении рецептора nk1 EA017960B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0808030.1A GB0808030D0 (en) 2008-05-01 2008-05-01 Novel compounds
PCT/EP2009/055190 WO2009133135A1 (en) 2008-05-01 2009-04-29 Spiro (piperidine-4, 2 ' -pyrrolidine) -1- (3, 5- trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists

Publications (2)

Publication Number Publication Date
EA201071259A1 true EA201071259A1 (ru) 2011-10-31
EA017960B1 EA017960B1 (ru) 2013-04-30

Family

ID=39537192

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071259A EA017960B1 (ru) 2008-05-01 2009-04-29 Производные 1,8-диазоспиро[4,5]декан-8-карбоксамида, обладающие антагонистической активностью в отношении рецептора nk1

Country Status (22)

Country Link
US (2) US8367692B2 (ru)
EP (1) EP2300474B1 (ru)
JP (1) JP5524183B2 (ru)
KR (1) KR101645743B1 (ru)
CN (1) CN102083832B (ru)
AU (1) AU2009242120B2 (ru)
BR (1) BRPI0910530B8 (ru)
CA (1) CA2723062C (ru)
CY (1) CY1113458T1 (ru)
DK (1) DK2300474T3 (ru)
EA (1) EA017960B1 (ru)
ES (1) ES2395571T3 (ru)
GB (1) GB0808030D0 (ru)
HR (1) HRP20121018T1 (ru)
IL (1) IL208917A (ru)
MX (1) MX2010011985A (ru)
PL (1) PL2300474T3 (ru)
PT (1) PT2300474E (ru)
RS (1) RS52719B (ru)
SI (1) SI2300474T1 (ru)
WO (1) WO2009133135A1 (ru)
ZA (1) ZA201007519B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2484674A1 (en) 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
CN109651368A (zh) * 2018-12-17 2019-04-19 武汉药明康德新药开发有限公司 4-甲酸甲酯-2-氧-1,8-二氮杂螺[4.5]癸烷-8-甲酸叔丁酯的制备方法
IL298589A (en) * 2020-06-02 2023-01-01 Nerre Therapeutics Ltd Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215706D0 (en) 1992-07-23 1992-09-09 Tollpass Limited Parking toll collecting system
EP0702681A1 (en) 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin antagonists
US6274604B1 (en) 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
US7482365B2 (en) * 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP4389478B2 (ja) * 2002-05-29 2009-12-24 田辺三菱製薬株式会社 新規ピペリジン誘導体
JP4380508B2 (ja) * 2003-11-28 2009-12-09 田辺三菱製薬株式会社 医薬組成物
JP2005154380A (ja) * 2003-11-28 2005-06-16 Tanabe Seiyaku Co Ltd ピペリジン誘導体
US7390905B2 (en) * 2003-11-28 2008-06-24 Mitsubishi Tanabe Pharma Corporation Piperidine compound and process for preparing the same
GB0514707D0 (en) * 2005-07-18 2005-08-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN102083832B (zh) 2013-06-05
PL2300474T3 (pl) 2013-03-29
ES2395571T3 (es) 2013-02-13
EP2300474A1 (en) 2011-03-30
US8633214B2 (en) 2014-01-21
DK2300474T3 (da) 2012-12-10
JP2011518861A (ja) 2011-06-30
BRPI0910530A2 (pt) 2015-08-18
IL208917A (en) 2014-06-30
MX2010011985A (es) 2011-02-24
US20110053922A1 (en) 2011-03-03
WO2009133135A1 (en) 2009-11-05
KR101645743B1 (ko) 2016-08-04
IL208917A0 (en) 2011-01-31
US20130123250A1 (en) 2013-05-16
EP2300474B1 (en) 2012-10-03
PT2300474E (pt) 2013-01-07
SI2300474T1 (sl) 2013-01-31
KR20110015421A (ko) 2011-02-15
ZA201007519B (en) 2011-11-30
GB0808030D0 (en) 2008-06-11
CA2723062A1 (en) 2009-11-05
CA2723062C (en) 2016-07-05
BRPI0910530B1 (pt) 2020-02-11
RS52719B (en) 2013-08-30
CY1113458T1 (el) 2016-06-22
JP5524183B2 (ja) 2014-06-18
HRP20121018T1 (hr) 2013-01-31
BRPI0910530B8 (pt) 2021-05-25
US8367692B2 (en) 2013-02-05
AU2009242120A1 (en) 2009-11-05
CN102083832A (zh) 2011-06-01
EA017960B1 (ru) 2013-04-30
AU2009242120B2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
CY1118879T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
MY142807A (en) Benzimidazole derivative and use thereof.
MX2009010024A (es) Nuevo compuesto de adenina.
WO2007125321A3 (en) Purine and deazapurine derivatives as pharmaceutical compounds
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
UA110259C2 (ru) Производные пиролопиримидина и пурина
AR041055A1 (es) Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto
MXPA05008619A (es) Derivados novedosos de 2-piridincarboxamida.
AR063101A1 (es) Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE540037T1 (de) Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
MX347423B (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
EA201790713A1 (ru) N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B
MX2010006230A (es) Derivados de arilamida substituidos con triazol y su uso como antagonistas de receptor purinergico p2x3 y/o p2x2/3.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
TW200612936A (en) Indole derivatives
GB0701365D0 (en) Novel pharmaceutical compositions
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU